RNA interference stock buzzes.
FROM ALNYLAM'S WEBSITE...ANLY released positive clinical trial results. Alnylam Reports Positive Clinical Results – with up to 94% Knockdown of Serum Transthyretin (TTR) – for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
What does 94% knockdown mean?
It means the stock is up. And RNA interference seems to have a future.
And yes, I own the stock. Not much--I am of modest means--but it's still fun to pretend I'm clairvoyant.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment